Hormone Replacement Therapy

Department of Health and Social Care written question – answered on 3rd August 2020.

Alert me about debates like this

Photo of Steve McCabe Steve McCabe Labour, Birmingham, Selly Oak

To ask the Secretary of State for Health and Social Care, what progress his Department has made on tackling the shortage of Hormone Therapy Replacement patches.

Photo of Steve McCabe Steve McCabe Labour, Birmingham, Selly Oak

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the (a) effectiveness and (b) safety of using alternatives to Hormone Therapy Replacement patches.

Photo of Jo Churchill Jo Churchill The Parliamentary Under-Secretary for Health and Social Care

We have been working closely with all suppliers of Hormone Replacement Therapy (HRT) preparations to maintain overall supply to patients. Supplies of alternative HRT products continue to remain available and the situation has been improving steadily since the end of February 2020.

The National Institute for Health and Care Excellence has made an assessment of the clinical and cost effectiveness of HRT, including transdermal patches, and has made recommendations on their use in its guideline on menopause: diagnosis and management [NG23].

The safety and efficacy of individual products that are authorised for the relief of oestrogen deficiency symptoms associated with the menopause are assessed at the time each product is licensed and safety is continuously monitored once it is on the market.

Most post-marketing studies examine the safety of HRT products as a group and the safety of HRT products as a class has been kept under continuous review by the Medicines and Healthcare products Regulatory Agency (MHRA) in conjunction with its independent scientific advisory body, the Commission on Human Medicines (CHM) and its Expert Advisory Group on Medicines for Women’s Health. Likewise, the safety of licensed medicines and herbal products that are used as alternatives to HRT are continuously monitored by the MHRA and advice sought from the CHM, as needed, when new safety issues arise.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.